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Abstract Hypoxanthine^guanine^xanthine phosphoribosyl-
transferase (HGXPRT) from Plasmodium falciparum catalyzes
the phosphoribosylation of hypoxanthine, guanine and xanthine.
The functionally active form of HGXPRT is a tetramer but
interface residues do not contribute to catalysis. Here we report
the characterization of an interface mutant Y96C, which has a
decreased kcat, an increase in the Km for phosphoribosyl
pyrophosphate (PRPP) and no change in Km for the purine
bases when compared to the wild type enzyme. The mutant
enzyme does not tetramerize in the presence of PRPP, unlike
the wild type in which the tetramer is stabilized by PRPP. This
is the first report of a HGXPRT mutation, at a unique inter-
face where non-adjacent subunits interact, that impairs catal-
ysis. , 2002 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Introduction
The purine salvage enzyme, hypoxanthine^guanine phos-
phoribosyltransferase (HGPRT) is an important drug target
in parasitic protozoans [1]. The use of 6-mercaptopurine and
6-thioguanine in the treatment of cancer and, allopurinol in
the treatment of certain parasitic diseases stems from the abil-
ity of HGPRT to convert these purine analogs into toxic
metabolites [2,3]. Extensive biochemical and structural studies
have been carried out on this enzyme from di¡erent organ-
isms. In all HGPRTs studied so far, the Km for the purine
base is in the low micromolar range while the Km for phos-
phoribosyl pyrophosphate (PRPP) is higher than that of the
corresponding purine [4]. All HGPRTs in the crystal struc-
tures reported so far are either dimers or tetramers [4]. In
solution, however, various factors such as presence of sub-
strates, ionic strength and pH in£uence the oligomeric status
of HGPRTs [5^8]. There is no concrete evidence for the direct
participation of residues in the interfaces in catalysis as they
are far away from the active site. An extensive network of
hydrogen bonds links the subunits of the oligomers. Mutation
of lysine68 to alanine at the dimer interface makes the human
HGPRT a cooperative enzyme, indicating that cross-talk be-
tween the active sites in the subunits could be mediated by this
hydrogen-bonded network [9].
The tetrameric structure of Plasmodium falciparum
HGXPRT (hypoxanthine^guanine^xanthine phosphoribosyl-
transferase; HGPRT from this parasitic protozoan has an
additional speci¢city for xanthine [10] and hence, referred to
as HGXPRT in this paper) in the crystal generates three
unique interfaces [11]. In this paper we represent these inter-
faces with respect to the loss of accessible surface area on
tetramer formation, with the interface getting buried, the
most being the dimer interface followed by the tetramer inter-
face and ¢nally, the least buried interface being called the
diagonal interface. In this report we present the expression,
puri¢cation and characterization of a mutant P. falciparum
HGXPRT wherein the mutation tyrosine96 to cysteine is lo-
cated in the diagonal interface. This study, for the ¢rst time,
shows that a mutation in this interface of the protein quater-
nary structure impairs tetramer formation leading to a dra-
matic reduction in catalytic e⁄ciency of HGXPRT.
2. Materials and methods
2.1. Chemicals and reagents
All chemicals used in enzyme assays including hypoxanthine, gua-
nine, xanthine, PRPP and MgCl2 were from Sigma Chemical Com-
pany, St. Louis, MO, USA. Escherichia coli SP609 was a gift from Dr.
Per Nygaard, University of Copenhagen, Denmark. Bacterial growth
media were purchased from HiMedia Laboratories Limited, Mumbai,
India. Hypoxanthine, guanine and xanthine stock solutions (50 mM)
were made in 0.4 N NaOH. PRPP was dissolved in water. For the
purpose of HGXPRT activation, PRPP, hypoxanthine and dithio-
threitol (DTT) were further diluted into 10 mM potassium phosphate,
pH 7.0 and immediately used.
2.2. Y96C HGXPRT construction, expression and puri¢cation
Y96C HGXPRT was obtained as a consequence of a PCR error
introduced during ampli¢cation of P. falciparum HGXPRT gene with
P2A mutation. The construction of P2A HGXPRT was reported ear-
lier [12]. During the cloning of P2A HGXPRT in the E. coli expres-
sion vector pTrc99A, recombinants carrying an insert of the expected
size were checked for expression of enzymatically active HGXPRT by
functional complementation in E. coli SP609 (ara, vpro-gpt-lac, thi,
hpt, purH, J str A) [13]. Colonies were grown in minimal medium
using protocols described earlier [14]. One of the recombinants, which
exhibited di¡erential ability to growth in minimal medium supple-
mented with purine bases, was subjected to DNA sequencing and
found to carry a Y96 to C mutation apart from P2 to A. Y96C
HGXPRT gene was subcloned into the expression vector pET23d
0014-5793 / 02 / $22.00 K 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
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and overexpressed in the E. coli strain BL21(DE3). The induction
conditions were the same as that reported for human HGPRT [12].
Protocols for puri¢cation of P2A and Y96C HGXPRTs were identical
to that reported for wild type P. falciparum HGXPRT [15]. All three
hyperexpressed proteins used in this study were veri¢ed for their iden-
tity on a HP 1101 electrospray mass spectrometer by direct injection
of the sample. Protein estimation was done by the Bradford method
using bovine serum albumin (BSA) as standard [16].
2.3. Enzyme assays
Reactions carried out at room temperature were monitored spec-
trophotometrically using a Shimadzu UV 1601 spectrophotometer.
The conditions used for monitoring hypoxanthine, guanine and xan-
thine phosphoribosylation by HGXPRT were exactly as reported ear-
lier [15]. Activation conditions were again, similar to that used for
wild type HGXPRT [15]. Brie£y, after puri¢cation Y96C HGXPRT
was bu¡er exchanged into 10 mM potassium phosphate, pH 7.0. This
protein was concentrated and used for activation. Activation was
carried out at a protein concentration of 27 WM, in 10 mM potassium
phosphate, pH 7.0, containing 200 WM PRPP, 60 WM hypoxanthine
and 5 mM DTT. This mixture was stored at 4‡C and activity of the
enzyme was measured after 40 h of incubation. For determining the
Km of PRPP for P2A HGXPRT, PRPP concentrations were varied
between 4.0 and 0.01 mM in the hypoxanthine phosphoribosylation
reactions, 4.0 and 0.025 mM for the guanine and xanthine phospho-
ribosylation reactions. Hypoxanthine and guanine concentrations
were held at 100 WM while xanthine was ¢xed at 300 WM for the
estimation of Km for PRPP. For determining Km for the purines,
the PRPP concentration was held constant at 1.6 mM and purine
concentrations were varied between 100.0 and 5.0 WM for hypoxan-
thine phosphoribosylation, 100.0 and 2.5 WM for guanine phospho-
ribosylation and, 300.0 and 2.5 WM for xanthine phosphoribosylation.
P2A concentration used in all the kinetic studies was 0.22 WM.
Hypoxanthine and guanine concentrations were maintained at
100 WM, and xanthine at 300 WM while PRPP concentrations were
varied between 4.0 and 0.2 mM for estimation of Km for PRPP for
Y96C HGXPRT. PRPP was held constant at 4 mM while individual
purine concentrations were varied between 100.0 and 5.0 WM for hy-
poxanthine phosphoribosylation, 100.0 and 2.5 WM for guanine phos-
phoribosylation and 300.0 and 2.5 WM for xanthine phosphoribosyla-
tion for estimating the Kms for the purines. Y96C concentration used
in all the kinetic studies was 0.54 WM. Kinetic constants for P2A and
Y96C HGXPRTs were determined as reported by Subbayya et al. [15].
2.4. Size exclusion chromatography
For examining the oligomeric status of P2A and Y96C HGXPRTs,
size exclusion chromatography was carried out using a Superdex-200
column (1U30 cm) attached to an Akta1 Basic HPLC. Cytochrome
C (12.4 kDa), carbonic anhydrase (29.0 kDa), BSA (66.0 kDa), alco-
hol dehydrogenase (150.0 kDa) and L-amylase (200.0 kDa) were used
as standards for gel ¢ltration. Blue dextran was used to determine the
void volume of the column. Elution was monitored at 220, 254 and
280 nm. The column was equilibrated and run with the assay bu¡er
consisting of 100 mM Tris^HCl, pH 7.4, 12 mM MgCl2 and 1 mM
DTT. 100 Wg protein in the same bu¡er was applied on to the column.
Oligomeric status in the presence of PRPP was determined by equili-
brating the column with 50 WM PRPP in the above bu¡er. 100 Wg of
protein preincubated for 1 h with 1 mM PRPP was used.
2.5. Structure analysis
The tetrameric structure of P. falciparum HGXPRT was generated
by submitting the coordinates deposited in the protein data bank to
European Bioinformatics Institute to generate the multimer coordi-
nates. These coordinates were then analyzed by an in-house program
to check inter-atomic distances. The program Naccess was used to
determine the solvent accessibility of residues in the HGXPRT struc-
ture [17].
3. Results and discussion
In our earlier studies on P. falciparum HGXPRT, the re-
combinant, wild type parasite enzyme was generated using the
expression construct pPf1 in which the HGXPRT gene is
cloned into the E. coli expression vector pTrc99A [14]. As a
consequence of end-¢lling and blunt-ended ligation, the NcoI
site was not regenerated in this construct. To facilitate easy
removal of the HGXPRT gene as a cassette from expression
constructs, an NcoI site was introduced in the 5P-end by mu-
tation of Pro(2) (CCA) to Ala (GCA). While screening di¡er-
ent colonies for production of enzymatically active, recombi-
nant P2A HGXPRT by functional complementation in the
HGXPRT de¢cient E. coli strain, SP609, one recombinant
was found to lack the ability to grow on xanthine and guanine
and, could grow in minimal medium only in the presence of
hypoxanthine. Sequencing of this clone revealed that apart
from the introduced P2A mutation, an additional Y96C mu-
tation (TAT to TGT) was also present. This double mutant is
referred to as Y96C HGXPRT. This mutation must have been
introduced by Taq polymerase during ampli¢cation of the
P2A HGXPRT gene fragment.
Fig. 1. Growth of E. coli SP609 transformed with the expression
constructs for wild type, P2A and Y96C HGXPRTs in minimal me-
dium supplemented with no purine (dotted box), 500 WM hypoxan-
thine (E), 500 WM guanine (striped box) and 500 WM xanthine (F).
Cultures were induced with 0.3 mM IPTG. A600 values of liquid
cultures were measured after 15 h of growth at 37‡C. Experiments
were repeated independently at least three times and the antennae
indicate the standard deviation.
Table 1
Speci¢c activities of wild type, P2A and Y96C HGXPRTs before and after activationa
Enzyme Speci¢c activity (nmol min31 mg31) Fold increase in activity
Unactivated Activated
Hyp Gua Xan Hyp Gua Xan Hyp Gua Xan
Wild type 72 17 198 3240 2434 6490 45 141 33
P2A 49 20 207 2240 3157 9065 46 161 44
Y96C 12 7 14 87 40 229 7 6 16
aProtein concentrations in the assay were 0.27, 0.22 and 0.54 WM for wild type, P2A and Y96C HGXPRTs, respectively.
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As shown in Fig. 1 the wild type and P2A HGXPRT were
able to complement hypoxanthine, guanine and xanthine de-
¢ciencies in E. coli SP609 with equal e⁄ciency. Y96C
HGXPRT was able to support E. coli SP609 growth in the
presence of hypoxanthine only, with guanine and xanthine
phosphoribosylation activities being insigni¢cant. These re-
sults indicate that mutation of proline2 to alanine in P. falci-
parum HGXPRT does not alter its substrate speci¢cities and
the di¡erences seen on complementation with Y96C
HGXPRT are due to mutation of tyrosine 96 to cysteine.
Though complementation studies indicated the production
of active wild type, P2A and Y96C HGXPRTs from pTrc99A
constructs in E. coli SP609, large amounts of hyper-expressed
protein on SDS^PAGE could be seen only in the case of wild
type and P2A and, not with Y96C HGXPRT. Hence, Y96C
HGXPRT was subcloned into the T7 expression vector
pET23d and expression in E. coli BL21(DE3) yielded large
amounts of recombinant protein. All the three proteins used
in the study were puri¢ed using similar protocols [15], ana-
lyzed by electrospray mass spectrometry and found to have
the molecular weights of 26226 (26231, wild type HGXPRT),
26204 (26205, P2A HGXPRT) and 26140 Da (26145, Y96C
HGXPRT). The numbers in parentheses are the calculated
molecular weights. All these masses correspond to proteins
without the N-terminal methionine.
The speci¢c activities for the wild type [15] and P2A
HGXPRTs were almost identical while Y96C HGXPRT ex-
hibited a signi¢cant drop in activity (Table 1). Surprisingly,
unlike results from in vivo complementation studies in E. coli,
xanthine and guanine phosphoribosylation activities of Y96C
HGXPRT in vitro, were at levels comparable to that of hy-
poxanthine. IMP, the product formed from hypoxanthine is in
the primary pathway of AMP and GMP formation and,
hence, there is greater cellular ease in the formation of these
purine nucleoside monophosphates. However, conversion of
GMP to AMP involves the enzyme GMP reductase whose
expression is up-regulated with increase in concentration of
GMP [18]. The discrepancy between complementation and
in vitro activity measurements could arise from low levels of
expression of Y96C HGXPRT in SP609 along with decreased
speci¢c activity for phosphoribosylation of guanine yielding
concentrations of GMP, probably insu⁄cient for the induc-
tion of signi¢cant quantities of GMP reductase required for
cell growth. The high Km for GMP (0.1 mM) for GMP re-
ductase [19,20] could also hamper growth of cells under con-
ditions of low in vivo concentrations of this nucleotide.
Our earlier studies with wild type P. falciparum HGXPRT
had shown that the low levels of activity could be dramati-
cally increased by preincubation with the substrates at high
protein concentrations [15,21]. Both P2A and Y96C
HGXPRTs were subjected to these activation conditions
and assayed for increase in activity. Increase in activities of
P2A HGXPRT was similar to that of the wild type with
minor variations (Table 1) while the activity of Y96C
HGXPRT, though exhibiting a 10-fold increase on activation,
was at least 25-fold lower than that of activated P2A
HGXPRT.
As shown in Table 2 the kcats and the Kms for the purine
bases and PRPP in the case of wild type and P2A HGXPRT
show only minor variations. This again indicates that the
enzymatic behavior of P2A is identical to that of the wild
type, justifying the use of this mutant for all comparative
studies. In the case of Y96C HGXPRT, the Km for PRPP is
highly elevated while Km for the purine bases is not signi¢-
Table 2
Kinetic constants for the P. falciparum wild type, P2A HGXPRT and Y96C HGXPRT forward reactions
Enzyme kcat (s31) Km (WM) kcat/Km (WM31 s31)
HPRT reaction
Hypoxanthine PRPP Hypoxanthine PRPP
Wild type 1.42 6 1 27 1.42 0.05
P2A 0.89 0.7 22 1.37 0.04
Y96C 0.04 1.5 1003 0.03 3.7U1035
GPRT reaction
Guanine PRPP Guanine PRPP
Wild type 1.06 1.5 80 0.71 0.01
P2A 1.19 0.9 119 1.31 0.01
Y96C 0.02 3.2 4230 5.7U1033 4.2U1036
XPRT reaction
Xanthine PRPP Xanthine PRPP
Wild type 2.84 146 141 0.02 0.02
P2A 4.13 120 84 0.01 0.05
Y96C 0.10 189 1330 5.3U1034 7.5U1035
Fig. 2. Gel ¢ltration pro¢le of P2A and Y96C HGXPRTs. a: P2A
(100 Wg) in assay bu¡er. b: P2A (100 Wg) in assay bu¡er with
PRPP. c: Y96C (100 Wg) in assay bu¡er. d: Y96C (100 Wg) in assay
bu¡er with PRPP. Numbers indicate elution volume (ml) of the
peaks.
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cantly altered (Table 2). Hence, in the kinetic studies of Y96C
HGXPRT, PRPP concentrations were maintained at 4 mM to
determine Km for the purine bases. However, the reaction
velocity of this mutant did not saturate even at this high
concentration of PRPP. Hence, the PRPP Kms for Y96C,
reported in this paper, might be lower than the actual values,
with purine base Kms being apparently higher.
Our earlier studies have shown that the oligomer formation
of P. falciparum HGXPRT is dependent on ionic strength of
the bu¡er and presence of PRPP. The enzyme is a dimer in
the assay bu¡er (100 mM Tris^HCl, pH 7.4, 12 mM MgCl2)
with addition of PRPP facilitating tetramer formation. These
studies on the wild type enzyme have also shown that activa-
tion from a low-activity form to a high-active form involves
conversion from dimers to tetramers (unpublished observa-
tions). Fig. 2, that summarizes the results obtained from size
exclusion chromatography analysis of P2A and Y96C
HGXPRTs, indicates that in the former enzyme like with
the wild type, tetramer formation is seen on addition of
PRPP. Like the wild type, increase in activity is seen with
P2A on activation with PRPP and hypoxanthine. However,
Y96C HGXPRT remains a dimer even on incubation with
PRPP (Fig. 2). Activity of Y96C HGXPRT does increase
many fold on activation (Table 1), indicating that low levels
of active tetramers are indeed being formed. These tetramers
are probably not as stable as in the wild type and P2A
HGXPRT, consequently the speci¢c activities never reach a
high level.
Examination of the tetrameric HGXPRT structure indicates
that Y96 is located in an interface, which involves cross-talk
between non-adjacent subunits (Fig. 3a,b). Analysis of solvent
accessibility of Y96 indicates that this residue in the monomer
is 22% buried. On dimerization the buried surface of this res-
idue is 26%, with tetramerization increasing buried area to
76%. Formation of HGXPRT dimer, leads to 2812 AS 2 of
the total surface area getting buried, which increases by fur-
ther 2070 AS 2 on tetramerization [11]. Of this total area of
4882 AS 2, which gets buried, 135 AS 2 is contributed by Y96.
The disposition of the various residues surrounding Y96 in the
tetrameric HGXPRT, at a distance of 4 AS is shown in Fig. 4.
The diagonal interface contacts arise from the interactions of
Y96 in subunit B with E55, R92, I93 and Y96 in subunit C.
Similar contacts are seen between subunits A and D.
The studies on Y96C reported in this paper indicate that
replacement of tyrosine96 by cysteine, which leads to a reduc-
tion in occupied surface area by 90 AS 2, results in dramatic
impairment of HGXPRT activity. The introduction of a
smaller residue, cysteine, may create a cavity at this interface
making the tetramer unstable. Formation of tetrameric
HGXPRT on addition of PRPP and the need for activation
hint at subtle rearrangements being induced in individual sub-
units on oligomerization (unpublished observations). The ex-
act nature of these rearrangements is not clear. However,
structural evidence exists for conformational changes that oc-
cur in individual subunits on substrate binding [23]. The pre-
dominant motion is that of the active site loop II that £ips by
25 AS to cover the active site when ligands are bound [24]. In a
recent study, it has been found that inhibitor binding stabil-
izes a unique segment located at the ‘diagonal interface’ of the
active tetramer in human HGPRT. In the human enzyme, the
residue corresponding to Y96 is N87 and it has been shown
by H/D exchange that the region around this residue in the
protein exchanges hydrogen at a slower rate on inhibitor
binding [6].
Fig. 3. a: Interaction of non-adjacent subunits B and C in P. falci-
parum HGXPRT tetramer shown along with inhibitor (Immucil-
linHP) bound in the active site (Protein Data Bank, ID code 1cjb)
[22]. Though all active sites are occupied in the deposited structure,
this ¢gure, for the sake of clarity, shows inhibitor complexed with
subunit B only. b: Subunits B and C rotated to highlight the rela-
tive orientation of Y96 at the ‘diagonal interface’. Y96 is shown in
ball and stick in (a) and (b). These ¢gures were generated using
Molscript [28].
Fig. 4. Residues contacting Y96 in subunit B at a distance of 4 AS
in the HGXPRT tetramer. Letters in parentheses indicate the sub-
unit. Two adjacent residues on either side of Y96 were ignored for
computing the contacts.
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In HGXPRT, Y96 is located at the C-terminal end of helix3
and is more than 10 AS away from the catalytic pocket in any
of the four subunits of the tetramer (Fig. 3a). Sequence com-
parison of this segment with other HGPRTs indicates the
presence of large diversity in this segment. Small molecules
designed to disrupt the tetramer could therefore, be targeted
to this unique region in HGPRTs. Non-active site segments
crucial for oligomerization, but which are unique to di¡erent
species, can therefore be exploited in species-speci¢c drug de-
sign. Such an approach has been successfully exploited in the
case of triose phosphate isomerase from P. falciparum, thymi-
dylate synthase from Lactobacillus casei and the HIV protease
[25^27].
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